STOCK TITAN

Fortrea Holdings Stock Price, News & Analysis

FTRE Nasdaq

Welcome to our dedicated page for Fortrea Holdings news (Ticker: FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.

Fortrea Holdings Inc. (NASDAQ: FTRE) is a global contract research organization and provider of clinical development solutions to the life sciences industry. This news page aggregates company press releases and market updates related to FTRE, giving readers a focused view of how Fortrea operates as a public company and clinical development partner.

According to its own descriptions, Fortrea partners with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies. News about the company frequently highlights its work in phase I–IV clinical trial management, clinical pharmacology and consulting services, as well as its experience across more than 20 therapeutic areas and operations in about 100 countries.

Visitors can expect news items covering a range of topics, including quarterly and year-to-date financial results, guidance updates, cost-saving initiatives, and capital structure actions such as tender offers for senior secured notes. Fortrea also issues releases on leadership and governance developments, such as board appointments and executive hires, and on strategic collaborations with other organizations involved in areas like cell and gene therapy development and delivery.

Because Fortrea is listed on The NASDAQ Stock Market LLC under the symbol FTRE, its news flow also includes announcements about participation in healthcare and investor conferences, earnings calls and webcasts. Together, these updates provide insight into how Fortrea manages its clinical development services business, interacts with the investment community and responds to developments in its operating environment.

For investors, analysts and industry observers, following FTRE news offers a way to monitor the company’s financial reporting, governance changes, collaborations and other material events that Fortrea discloses through press releases and related communications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
partnership clinical trial
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
conferences
-
News
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
management
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.61%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
management
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences earnings
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none

FAQ

What is the current stock price of Fortrea Holdings (FTRE)?

The current stock price of Fortrea Holdings (FTRE) is $10.27 as of February 12, 2026.

What is the market cap of Fortrea Holdings (FTRE)?

The market cap of Fortrea Holdings (FTRE) is approximately 1.1B.
Fortrea Holdings

Nasdaq:FTRE

FTRE Rankings

FTRE Stock Data

1.07B
91.88M
0.5%
111.46%
11.57%
Biotechnology
Services-medical Laboratories
Link
United States
DURHAM

FTRE RSS Feed